Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control. Loco Regional Anesthesia (LRA) is one of the major treatments in resuscitation anesthesia for both anesthesia and analgesia. LRA allows effective and almost immediate pain control by blocking nerve afferents in a given area. LRA could decrease the inflammatory response during crises and accelerate resolution of the crisis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• patients adult \>18 years
• patients with vaso-occlusive crisis
Locations
Other Locations
Guadeloupe
Chu de La Guadeloupe
RECRUITING
Pointe-à-pitre
Contact Information
Primary
Valérie Hamony Soter
valerie.soter@chu-guadeloupe.fr
+590590934677
Backup
Mélanie Petapermal
melanie.petapermal@chu-guadeloupe.fr
+590590934667
Time Frame
Start Date: 2025-02-05
Estimated Completion Date: 2027-02-05
Participants
Target number of participants: 34
Treatments
RA-Group
When a sickle cell patient comes to the emergency department with pain such as vaso-occlusive crises, we will offer them the opportunity to participate in the study. Inclusion will therefore occur before the choice of analgesic technique. The patient will receive the treatment they have chosen (with or without regional anesthesia). Depending on their choice and/or any contraindications (e.g., morphine intolerance or allergy to ropivacaine), they will be placed in the RA group (if they received regional anesthesia) or the non-RA group (if they did not receive it).
Non-RA group
When a sickle cell patient comes to the emergency department with pain such as vaso-occlusive crises, we will offer them the opportunity to participate in the study. Inclusion will therefore occur before the choice of analgesic technique. The patient will receive the treatment they have chosen (with or without regional anesthesia). Depending on their choice and/or any contraindications (e.g., morphine intolerance or allergy to ropivacaine), they will be placed in the RA group (if they received regional anesthesia) or the non-RA group (if they did not receive it).
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de la Guadeloupe